Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Neoplasms 5Venous Thromboembolism 4Venous Thrombosis 3Pulmonary Embolism 3Thrombosis 1Prostatic Neoplasms 1Myeloproliferative Disorders 1Multiple Endocrine Neoplasia Type 1 1Hot Flashes 1Embolism 1Cushing Syndrome 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Advanced Non-small Cell Lung Cancer 1

Interventions

Fulvestrant 5Exercise 5Eating 5Standard of Care 3Sodium Chloride 3Diet 3Alpelisib 3ribociclib 2gallium Ga 68 dotatate 2exemestane 2Vitamin D 2Tamoxifen 2Magnetic Resonance Spectroscopy 2Letrozole 2Ethanol 2Blood Specimen Collection 2Anastrozole 2zopiclone 1ziprasidone 1veliparib 1testosterone undecanoate 1testosterone enanthate 1pazopanib 1mirabegron 1methyl hydroxyethyl cellulose 1lenvatinib 1fluorocholine 1evolocumab 1dimethandrolone-undecanoate 1cyclopropapyrroloindole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multiple Endocrine Neoplasia Type 1 × Dabigatran × Clear all
NCT05471817 2022-11-22

A Study to Learn How the Study Drug Elinzanetant (BAY 3427080) Affects the Way the Drug Dabigatran Moves Into, Through and Out of the Body in Healthy Male and Female Participants

Bayer

Phase 1 Completed
20 enrolled
Endocrine

Multiple Endocrine Neoplasia Type 1, Hot Flashes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡